QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAsure Methylation Test, a novel CE-marked molecular diagnostic test for use in differentiating patients’ risk of developing cervical cancer.
{iframe}http://www.prnewswire.com/news-releases/qiagen-launches-qiasure-methylation-test-to-determine-cervical-cancer-risk-583011291.html{/iframe}